Meeting
2023 ASCO Annual Meeting
A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK.
Authors
Salah-Eddin Al-Batran
Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, and Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt, Germany
Salah-Eddin Al-Batran , Sylvie Lorenzen , Peter C. Thuss-Patience , Nils Homann , Michael Schenk , Udo Lindig , Vera Heuer , Albrecht Kretzschmar , Eray Goekkurt , Georg Martin Haag , Jorge Riera-Knorrenschild , Claus Bolling , Ralf-Dieter Hofheinz , Stefan Angermeier , Thomas Jens Ettrich , Alexander Reinhard Siebenhuener , Christina Kopp , Claudia Pauligk , Thorsten Oliver Goetze
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT03421288
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4177)
DOI
10.1200/JCO.2023.41.16_suppl.TPS4177
Abstract #
TPS4177
Poster Bd #
495a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
First Author: Salah-Eddin Al-Batran
Poster
2022 ASCO Annual Meeting
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
First Author: Thorsten Oliver Goetze
Poster
2021 ASCO Annual Meeting
MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.
First Author: Yelena Y. Janjigian
Poster
2014 ASCO Annual Meeting
HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.
First Author: Ralf Hofheinz